TBPH Theravance Biopharma, Inc. Stock Quote

TBPH [NASD]

Healthcare | Biotechnology | Cayman Islands

Index	-	P/E	-	EPS (ttm)	-4.11	Insider Own	5.30%	Shs Outstand	65.67M	Perf Week	-20.19%
Market Cap	487.72M	Forward P/E	18.64	EPS next Y	0.37	Insider Trans	0.00%	Shs Float	61.17M	Perf Month	-49.00%
Income	-264.20M	PEG	-	EPS next Q	-0.55	Inst Own	84.80%	Short Float	3.43%	Perf Quarter	-60.82%
Sales	64.20M	P/S	7.60	EPS this Y	-4.90%	Inst Trans	14.25%	Short Ratio	1.63	Perf Half Y	-66.31%
Book/sh	-4.57	P/B	-	EPS next Y	46.50%	ROA	-59.20%	Target Price	-	Perf Year	-61.39%
Cash/sh	3.74	P/C	1.84	EPS next 5Y	54.10%	ROE	85.30%	52W Range	6.10 - 22.74	Perf YTD	-61.28%
Dividend	-	P/FCF	-	EPS past 5Y	3.50%	ROI	-96.60%	52W High	-69.70%	Beta	0.89
Dividend %	-	Quick Ratio	5.00	Sales past 5Y	11.30%	Gross Margin	-	52W Low	12.95%	ATR	0.74
Employees	359	Current Ratio	5.00	Sales Q/Q	-14.00%	Oper. Margin	-	RSI (14)	26.30	Volatility	10.52% 7.22%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	20.20%	Profit Margin	-	Rel Volume	0.42	Prev Close	6.88
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 03 AMC	Payout	-	Avg Volume	1.29M	Price	6.89
Recom	2.60	SMA20	-18.63%	SMA50	-39.90%	SMA200	-59.09%	Volume	335,541	Change	0.15%

Sep-15-21

Downgrade

JP Morgan

Overweight → Underweight

Aug-25-21

Downgrade

Morgan Stanley

Overweight → Underweight

$27 → $14

Aug-24-21

Downgrade

Cowen

Outperform → Market Perform

$42 → $14

Oct-14-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$32

Jul-07-20

Initiated

JP Morgan

Overweight

$29

Jun-15-20

Initiated

Morgan Stanley

Equal-Weight

$30

May-13-20

Initiated

Cowen

Outperform

$42

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$25 → $30

Nov-06-19

Upgrade

Robert W. Baird

Underperform → Neutral

$22 → $18

Oct-29-19

Initiated

H.C. Wainwright

Buy

$25

Mar-29-18

Resumed

Piper Jaffray

Overweight

$45

Aug-17-17

Initiated

Evercore ISI

Outperform

$45

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$55

May-11-17

Reiterated

Needham

Buy

$40 → $45

Dec-21-16

Initiated

Needham

Buy

$40

Nov-03-16

Initiated

Piper Jaffray

Overweight

Oct-12-16

Downgrade

Robert W. Baird

Neutral → Underperform

$19 → $24

Aug-03-16

Downgrade

BofA/Merrill

Neutral → Underperform

Jun-20-16

Reiterated

Leerink Partners

Outperform

$26 → $29

Jun-20-16

Initiated

Guggenheim

Buy

$30

Sep-21-21 10:00AM	Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround Zacks
Sep-17-21 07:40AM	Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win Zacks
Sep-16-21 10:55AM	Theravance (TBPH) to Cut Workforce, Hypotension Study Fails Zacks
Sep-15-21 05:13PM	Why Theravance Biopharma Stock Dived 16% Today Motley Fool -15.80%
07:38AM	The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga
06:31AM	Theravance Biopharma shares slide 34% premarket on news to cut 75% of workforce in strategic overhaul MarketWatch
06:06AM	Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio PR Newswire
06:05AM	Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension PR Newswire
04:57AM	Theravance Plunges as Potential Drug Fails, Forces 75% Cut in Headcount Investing.com
Sep-02-21 11:31AM	Why Is Theravance Bio (TBPH) Down 36.5% Since Last Earnings Report? Zacks +6.55%
Aug-26-21 12:56PM	Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update Zacks -5.40%
Aug-24-21 04:05PM	Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug? Investor's Business Daily -34.79%
03:02PM	Here's Why Theravance Biopharma Stock Is Tanking Today Motley Fool
12:17PM	Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide Benzinga
10:13AM	Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates Benzinga
09:14AM	Theravance (TBPH) Suffers 2nd Study Failure in Two Months Zacks
06:56AM	Theravance Stock Drops; Ulcerative-Colitis Drug Doesn't Meet Endpoint TheStreet.com
06:16AM	Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study Benzinga
Aug-23-21 04:51PM	Theravance Bio stock falls more than 20% after drug trial disappoints MarketWatch
04:05PM	Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis PR Newswire
Aug-09-21 01:39AM	Some Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Estimates Simply Wall St.
Aug-04-21 10:01AM	Theravance Biopharma, inc (TBPH) Q2 2021 Earnings Call Transcript Motley Fool
09:44AM	Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track Zacks
Aug-03-21 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:00PM	Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire
Aug-02-21 10:26AM	3 Strong Buy Stocks Trading at Steep Discounts TipRanks +6.47%
Jul-27-21 03:03PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-20-21 06:00AM	Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021 PR Newswire +5.61%
Jul-02-21 10:55AM	10 Best Defensive Stocks to Buy Now Insider Monkey
Jun-24-21 10:56PM	Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares PR Newswire
04:33PM	Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares PR Newswire
Jun-22-21 09:51AM	Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study Zacks
Jun-21-21 07:37AM	Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study Benzinga
06:05AM	Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 PR Newswire
04:09AM	Amazon, CureVac Rise Premarket; Coinbase Global Falls Investing.com
03:06AM	Theravance Plunges As Candidate For Covid-Related Lung Injury Fails Investing.com
Jun-03-21 11:31AM	Theravance Bio (TBPH) Down 13% Since Last Earnings Report: Can It Rebound? Zacks
May-09-21 04:50AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Slashed This Year's Estimates Simply Wall St.
May-06-21 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire
May-05-21 10:45AM	Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track Zacks
12:01AM	Theravance Biopharma Inc (TBPH) Q1 2021 Earnings Call Transcript Motley Fool
May-04-21 05:20PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update PR Newswire
03:15PM	Theravance Biopharma, Inc. to Host Earnings Call ACCESSWIRE
Apr-21-21 03:22AM	Increases to Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation Might Cool off for now Simply Wall St.
Apr-20-21 06:00AM	Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021 PR Newswire
Mar-25-21 11:30AM	Theravance Bio (TBPH) Up 10.1% Since Last Earnings Report: Can It Continue? Zacks
Mar-04-21 04:13AM	Are Theravance Biopharma, Inc. (NASDAQ:TBPH) Investors Paying Above The Intrinsic Value? Simply Wall St.
Mar-02-21 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire +5.21%
Feb-24-21 06:32AM	Theravance Biopharma Inc (TBPH) Q4 2020 Earnings Call Transcript Motley Fool
Feb-23-21 04:45PM	Theravance Biopharma: Q4 Earnings Insights Benzinga
03:15PM	Theravance Biopharma, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:16AM	Theravance Biopharma Earnings Preview Benzinga
Feb-10-21 06:00AM	Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire
Feb-09-21 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021 PR Newswire
Jan-14-21 12:00PM	2 Strong Buy Stocks Trading at Steep Discounts TipRanks
Jan-05-21 06:00AM	Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-19-20 01:06PM	Is TBPH A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-05-20 11:32AM	Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound? Zacks
Nov-17-20 06:00AM	Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference PR Newswire
Nov-09-20 12:17PM	Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line Zacks +6.40%
10:20AM	Analysts Have Lowered Expectations For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Its Latest Results Simply Wall St.
Nov-07-20 01:31AM	Theravance Biopharma Inc (TBPH) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:05PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
03:30PM	Theravance Biopharma, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 12:34PM	Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-27-20 01:19PM	Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Oct-22-20 06:00AM	Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 PR Newswire +5.31%
Oct-19-20 10:39AM	Hedge Funds Have Never Been This Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Sep-05-20 11:31AM	Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report? Zacks
Sep-01-20 06:00AM	Theravance Biopharma to Present at Upcoming Investor Conferences PR Newswire
Aug-07-20 01:27PM	Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2 Zacks -13.82%
Aug-06-20 06:35PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:34PM	Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Jul-30-20 12:34PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-27-20 06:00AM	Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020 PR Newswire
Jul-22-20 12:32PM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-02-20 06:00AM	Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors PR Newswire
Jun-29-20 03:50PM	Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH) Insider Monkey
Jun-26-20 12:04PM	Theravance Doses First Patient in Phase II Coronavirus Study Zacks
Jun-25-20 08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga
06:00AM	Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Jun-17-20 09:38PM	GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes Moody's -9.05%
Jun-15-20 09:57AM	Benzinga's Top Upgrades, Downgrades For June 15, 2020 Benzinga -6.61%
Jun-05-20 11:31AM	Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-02-20 09:02PM	Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 02:31PM	Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 01:57PM	Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-06-20 07:35PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-29-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-28-20 12:33PM	Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know Zacks
10:35AM	Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay Simply Wall St.
06:00AM	Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020 PR Newswire
Apr-23-20 06:00AM	Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 PR Newswire
Apr-20-20 06:00AM	Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis PR Newswire
Apr-14-20 04:41PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com
Apr-09-20 07:00AM	Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury PR Newswire +5.11%
Mar-25-20 11:30AM	Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue? Zacks -5.40%
Mar-23-20 06:32PM	Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 Investor's Business Daily
Mar-20-20 08:02PM	Seth Klarman Sees Bargains as the Market Heads Further Into Chaos GuruFocus.com

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WORBOYS PHILIP D	SVP, Research & Transl Science	Mar 09	Sale	20.00	8,829	176,580	343,679	Mar 11 07:00 PM
GRAHAM RICHARD A	SVP, Development	Dec 14	Sale	19.47	7,500	146,058	123,749	Dec 16 06:09 PM
WORBOYS PHILIP D	SVP, Research & Transl Science	Dec 03	Sale	18.00	4,246	76,428	319,395	Dec 07 06:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience